Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Miami
With
AstraZeneca
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
physician diagnosis of COPD
former smoking history of more than 10 pack-years
baseline post-bronchodilator one-second forced expiratory volume (FEV1) 50-80% of predicted, baseline FEV1 and forced vital capacity (FVC) ratio \<0.7
males and females, 40-80 years of age
regular use of a LAMA/LABA drug regimen for at least a month
You may not be if
women of childbearing potential who do not use accepted birth- control measures
pregnant and breast-feeding women
respiratory infection within 4 weeks of a test day
a Corona Virus Disease (COVID) vaccination \<3 months prior to study entry
ICS use (within 4 weeks of study entry)
ICS hypersensitivity
albuterol intolerance
use of beta-blocker medication (oral and ophthalmic)
use of systemic glucocorticosteroid medication within 6 wk prior to the screening visit
an acute COPD exacerbation within 6 wk of the screening day (defined as a need for antibiotic or systemic glucocorticoid therapy or emergency department (ED) visit/hospitalization)
current smoking or vaping tobacco or other products
Oxygen (O2) saturation of \<90% at-rest breathing room air
Long-term oxygen therapy (LTOT) required at rest
regular use of pulmonary vasodilators
systemic arterial systolic pressure \>150 mmHg and diastolic pressure \>100 mmHg on the test day
a \>40mmHg right ventricular systolic pressure (RVSP) by prior echocardiography
a documented COVID infection within 4 weeks of the screening day
Regular use of home oxygen at rest
Physician diagnosis of obesity hypoventilation syndrome
